Precision Biosciences (DTIL) Income from Continuing Operations (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Income from Continuing Operations of 8575000.0 for Q1 2026, up 59.69% year-over-year from 5369755.82 in Q1 2025, and down 165.96% quarter-over-quarter from 13000000.0 in Q4 2025.
Precision Biosciences (DTIL) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Income from Continuing Operations for 9 consecutive years, with 8575000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 59.69% year-over-year to 8575000.0; the TTM figure through Mar 2026 stood at 45389000.0 (up 23.13% YoY), while the FY2025 annual figure was 193190000.0, down 23.62% from the prior year.
- Income from Continuing Operations retreated to 8575000.0 in Q1 2026 per DTIL's latest filing, from 13000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 15566000.0 in Q2 2024 and bottomed at 35863000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 14505705.88 across 5 years, with a median of 13438000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 305.3% — and 2025, when it slumped 586.67%.
- Precision Biosciences' Income from Continuing Operations stood at 10861000.0 in 2022, then slipped by 23.73% to 13438000.0 in 2023, then tumbled by 77.66% to 23874000.0 in 2024, then jumped by 154.45% to 13000000.0 in 2025, then tumbled by 165.96% to 8575000.0 in 2026.
- Business Quant data shows DTIL's Income from Continuing Operations at 8575000.0 in Q1 2026, 13000000.0 in Q4 2025, and 27645000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -18.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.73 Mn |
| Mar 31, 2026 | -8.58 Mn |
| Dec 31, 2025 | 13.00 Mn |
| Sep 30, 2025 | -27.65 Mn |
| Jun 30, 2025 | -22.17 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Dec 31, 2024 | -23.87 Mn |
| Sep 30, 2024 | -29.46 Mn |
| Jun 30, 2024 | 15.57 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -13.44 Mn |
| Sep 30, 2023 | -11.18 Mn |
| Jun 30, 2023 | -7.58 Mn |
| Mar 31, 2023 | -11.88 Mn |
| Dec 31, 2022 | -10.86 Mn |
| Sep 30, 2022 | -14.03 Mn |
| Jun 30, 2022 | -35.86 Mn |
| Mar 31, 2022 | -34.23 Mn |
| Dec 31, 2021 | -30.71 Mn |
| Sep 30, 2021 | -22.12 Mn |